drugset / Trial / NCT07453875
LDRT Sequential NIPS Immunochemotherapy for Peritoneal Metastasis of Gastric and Colorectal Cancer
Phase 1
Not yet recruiting
9 enrolled
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
NaSingle-groupOpen-labelTreatment
Summary
There have been initial explorations on the treatment of peritoneal metastasis of gastric and colorectal cancer both at home and abroad. However, the comprehensive treatment plan of "LDRT + NIPEC + immunotherapy + systemic therapy" has not been reported either domestically or internationally. This study will explore the safety and efficacy of total abdominal low-dose radiotherapy followed by NIPEC and PD-1 treatment for peritoneal metastasis of gastric and colorectal cancer. 9-18 participants will be enrolled in this study. All will take part at Daping Hospital, Army Medical University.
Timeline
- Start
- 2026-05
- Primary completion
- 2027-11-30
- Completion
- 2027-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 1000 mg/m2 | — |
| Subject | Oxaliplatin | Small molecule | 30 mg/m2 | Intravenous |
| Subject | Oxaliplatin | Small molecule | 100 mg/m2 | Intravenous |
| Subject | S-1 | Small molecule | 80 mg/m2 | — |
| Subject | Tislelizumab | Monoclonal antibody | 100 mg | Intravenous |